What are the recommended treatment guidelines for community‑acquired pneumonia in outpatient, non‑ICU, and ICU settings?

Community-Acquired Pneumonia Treatment Guidelines

For outpatient CAP without comorbidities, use amoxicillin 1g three times daily, doxycycline 100mg twice daily, or a macrolide (if local pneumococcal resistance is <25%); for outpatients with comorbidities, use combination therapy with amoxicillin/clavulanate or a cephalosporin PLUS a macrolide or doxycycline, OR monotherapy with a respiratory fluoroquinolone. 1

Outpatient Treatment

Patients WITHOUT Comorbidities or Risk Factors for MRSA/Pseudomonas

Choose ONE of the following:

• Amoxicillin 1g three times daily (preferred first-line)
• Doxycycline 100mg twice daily
• Macrolide (azithromycin 500mg day 1, then 250mg daily; OR clarithromycin 500mg twice daily) - only if local pneumococcal resistance is <25% 1

Patients WITH Comorbidities*

*Comorbidities include: chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia 1

Option 1 - Combination Therapy (Preferred):

• Beta-lactam: Amoxicillin/clavulanate (500mg/125mg three times daily OR 875mg/125mg twice daily OR 2,000mg/125mg twice daily) OR cefpodoxime 200mg twice daily OR cefuroxime 500mg twice daily
• PLUS a macrolide or doxycycline (doses as above) 1

Option 2 - Monotherapy:

• Respiratory fluoroquinolone: Levofloxacin 750mg daily OR moxifloxacin 400mg daily OR gemifloxacin 320mg daily 1

Non-ICU Hospitalized Patients

Use combination therapy with a beta-lactam PLUS a macrolide, OR monotherapy with a respiratory fluoroquinolone. 1, 2

The combination approach provides broader coverage for typical and atypical pathogens, which is critical in hospitalized patients where severity is higher and diagnostic certainty may be limited.

ICU/Severe CAP Patients

Dual antibiotic therapy is mandatory: use a third-generation cephalosporin PLUS either a macrolide OR a respiratory fluoroquinolone. 2

Special Considerations for Severe CAP:

For Pseudomonas Risk Factors (prior respiratory isolation OR recent hospitalization with parenteral antibiotics in last 90 days):

• Use antipseudomonal beta-lactam PLUS aminoglycoside PLUS azithromycin or fluoroquinolone 1, 2

For MRSA Risk Factors:

• Add vancomycin OR linezolid, OR ceftaroline for resistant cases 2

Antibiotic Duration

The 2025 guidelines fundamentally changed duration recommendations based on clinical stability 3, 4:

Outpatient and Non-Severe Hospitalized CAP:

• 3 days minimum if clinical stability achieved by day 3 5, 3, 4
• 5 days if stability achieved by day 5 4
• Less than 5 days is now recommended rather than ≥5 days 5

Severe CAP (ICU patients):

• 5 or more days of antibiotics required 5

Clinical stability criteria must be met before stopping antibiotics: afebrile, hemodynamically stable, improving respiratory symptoms, able to take oral intake 4

This represents a major shift from the 2019 guidelines, which recommended longer courses. Multiple randomized trials and meta-analyses confirmed non-inferiority of shorter durations (3-7 days) versus longer treatments (>7 days), supporting reduced antibiotic exposure while maintaining efficacy 4.

Viral Testing and Antibiotic Decisions

For otherwise healthy outpatients with positive viral testing and CAP, the 2025 guidelines suggest NOT prescribing antibiotics, though this is based on very low-quality evidence 5. However:

• Prescribe antibiotics if: imaging shows pneumonia, patient has comorbidities, or patient requires admission 5
• This recommendation requires careful clinical judgment as the evidence quality is acknowledged as very low

Corticosteroids

Use corticosteroids in severe CAP (within 36 hours of admission), but NOT in nonsevere pneumonia 5, 2. Administration in severe cases decreases risk of ARDS and shortens treatment length 2.

Diagnostic Testing Considerations

Routine urinary antigen testing for pneumococcus or Legionella is NOT recommended in outpatient CAP 1. However:

• Test for both in severe CAP (conditional recommendation) 1
• Test for Legionella if outbreak association, recent travel, or severe disease 1
• Lung ultrasound is now supported for CAP diagnosis when performed by experienced clinicians 5, 3

Critical Pitfalls to Avoid

1. Do not use macrolide monotherapy in areas with >25% pneumococcal resistance - this is explicitly contraindicated 1
2. Do not undertreate severe CAP - ICU patients require dual therapy, not monotherapy
3. Do not continue antibiotics beyond clinical stability in non-severe CAP - the 2025 guidelines emphasize shorter durations 5, 3
4. Do not forget MRSA/Pseudomonas coverage when risk factors are present (prior isolation or recent hospitalization with IV antibiotics in last 90 days) 1